Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, ...

The new data from the 1,178-patient FIBRONEER-ILD study showed that the oral PDE 4B inhibitor was able to improve lung function in patients with progressive pulmonary fibrosis (PPF), a form of ...

Specifically, idiopathic pulmonary fibrosis (IPF) is a condition in which the lungs become scarred and breathing becomes ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Aerosol Delivery Devices Market Research Report In 2019, the aerosol delivery devices market is projected to reach $46.73 billion by 2027, ...

aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

Imagine feeling like you're trying to breathe through a straw, even when you're just sitting still. A simple walk across the ...